ankylosing spondylitis

What is ankylosing spondylitis?

Ankylosing spondylitis is a form of arthritis that primarily affects the spine, causing inflammation of the spinal joints. This leads to chronic pain and stiffness, especially in the lower back and hips. Over time, severe cases can result in new bone formation, causing vertebrae to fuse. It is an autoimmune condition typically diagnosed in young adults and is more common in men. While there is no cure, early diagnosis and treatment can significantly improve quality of life.

Key features

• Chronic Inflammation — Targets spine and sacroiliac joints, leading to pain and stiffness.
• Progressive Condition — Can lead to spinal fusion and reduced mobility over time.
• Autoimmune Origin — Linked to genetic marker HLA-B27 and immune system dysfunction.
• Early Onset — Typically appears in late adolescence to early adulthood.
• Treatment Options — Includes NSAIDs, biologics, physical therapy, and exercise.
• Systemic Effects — May affect eyes, heart, and lungs in some patients.
• Diagnosis Method — Confirmed via imaging (X-ray, MRI) and clinical evaluation.

Who is ankylosing spondylitis for?

Ankylosing spondylitis is not a product designed for consumers but a medical condition requiring long-term management. It primarily affects individuals under 45, especially men with a family history of the disease. Patients experiencing chronic back pain, morning stiffness lasting over 30 minutes, and improvement with exercise rather than rest should consult a rheumatologist. Early intervention is crucial to preserving mobility and function.

How does ankylosing spondylitis compare?

Unlike mechanical back pain, ankylosing spondylitis improves with movement and worsens with rest. It differs from osteoarthritis, which is degenerative and age-related, by being inflammatory and systemic. Compared to other autoimmune diseases like rheumatoid arthritis, it predominantly affects the axial skeleton. Treatment is more specialized than for common back pain, often requiring biologic medications such as TNF inhibitors or IL-17 blockers, which are not typically used in standard musculoskeletal conditions.